Glenmark Generics Inc.(GGL), the US subsidiary of Glenmark Generics Limited, has received the United States Food and Drug Administration (US FDA) has tentative approval for rizatriptan benzoate tablets.
Rizatriptan benzoate tablets is the generic version of Merck’s Maxalt tablets. According to IMS Health for the 12 month period ending June 2012, rizatriptan benzoate immediate release tablets achieved sales of US$ 315 million.
Glenmark's current portfolio consists of 81 products authorized for distribution in the US market and 41 ANDA's pending approval with the US FDA.